top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


The True Cost of a Poor Senior Hire in Life Sciences
A poor senior hire in Life Sciences can cost far more than recruitment fees and replacement expenses. Delayed milestones, lost productivity, weakened trust, and reduced willingness to speak up can all affect organizational performance. This article explores the financial and cultural impact—and how to reduce the risk before making a pivotal appointment.
sharonshieldsconsu
6 days ago4 min read


Succession Planning in Life Sciences: Your Most Overlooked Risk Management Tool
Succession planning in the life sciences industry is not a “nice to have” HR process—it’s a core element of risk management and business continuity. Unplanned leadership gaps can delay clinical trials, regulatory submissions, manufacturing, and product launches, directly impacting patients and revenue. In this article, we explore when, why and how life sciences organisations should approach leadership succession, the mission‑critical roles to prioritise, and practical steps.
sharonshieldsconsu
Nov 73 min read


How AI Is Transforming Clinical Development Drug Discovery Recruitment and Trial Management
Clinical development has always carried a painful contradiction. Science can point to promising biology, yet turning that promise into a tested therapy can take years of trial design, patient matching, site coordination and regulatory work. Many compounds fail late. Many trials struggle to enrol. Many teams spend too much time searching for patterns that sit hidden in papers, scans, genomic files and electronic health records.
sharonshieldsconsu
Oct 239 min read


GLP-1s Beyond Obesity: What the Evidence Really Shows
GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology.
Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders:
In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and
sharonshieldsconsu
Sep 283 min read
bottom of page